DK2858676T3 - Prostata-specifikke membran-antigen-antistof-lægemiddelkonjugater - Google Patents

Prostata-specifikke membran-antigen-antistof-lægemiddelkonjugater Download PDF

Info

Publication number
DK2858676T3
DK2858676T3 DK13732008.1T DK13732008T DK2858676T3 DK 2858676 T3 DK2858676 T3 DK 2858676T3 DK 13732008 T DK13732008 T DK 13732008T DK 2858676 T3 DK2858676 T3 DK 2858676T3
Authority
DK
Denmark
Prior art keywords
antistof
prostata
antigen
conjugates
medicine
Prior art date
Application number
DK13732008.1T
Other languages
English (en)
Inventor
Richard S Barnett
Feng Tian
Anna-Maria A Hays Putnam
Marco Gymnopoulos
Nick Knudsen
Andrew Beck
Ying Sun
Original Assignee
Ambrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ambrx Inc filed Critical Ambrx Inc
Application granted granted Critical
Publication of DK2858676T3 publication Critical patent/DK2858676T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK13732008.1T 2012-06-07 2013-06-07 Prostata-specifikke membran-antigen-antistof-lægemiddelkonjugater DK2858676T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261656883P 2012-06-07 2012-06-07
PCT/US2013/044850 WO2013185117A1 (en) 2012-06-07 2013-06-07 Prostate-specific membrane antigen antibody drug conjugates

Publications (1)

Publication Number Publication Date
DK2858676T3 true DK2858676T3 (da) 2019-05-13

Family

ID=48699944

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13732008.1T DK2858676T3 (da) 2012-06-07 2013-06-07 Prostata-specifikke membran-antigen-antistof-lægemiddelkonjugater

Country Status (14)

Country Link
US (2) US10800856B2 (da)
EP (2) EP3536700A1 (da)
JP (1) JP6425650B2 (da)
KR (1) KR102143664B1 (da)
CN (3) CN116514899A (da)
AU (2) AU2013270686B2 (da)
CA (1) CA2874854C (da)
DK (1) DK2858676T3 (da)
ES (1) ES2725329T3 (da)
IL (3) IL235895B (da)
MX (2) MX363116B (da)
NZ (2) NZ703298A (da)
SG (2) SG11201408153YA (da)
WO (1) WO2013185117A1 (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
BR112013003522B1 (pt) 2010-08-17 2021-05-25 Ambrx, Inc. polipeptídeos relaxina modificados compreendendo um aminoácido não codificado naturalmente, seu método de preparação e seu uso, bem como ácido nucleico e célula hospedeira
EP2850059A4 (en) 2012-05-15 2016-06-29 Concortis Biosystems Corp CONJUGATES OF MEDICATION, METHODS OF CONJUGATION AND USE THEREOF
EP3488870B1 (en) 2012-06-19 2024-03-20 Ambrx, Inc. Anti-cd70 antibody drug conjugates
CN105358174B (zh) 2013-03-15 2019-03-15 酵活有限公司 具细胞毒性和抗有丝分裂的化合物以及其使用方法
FR3005051A1 (fr) * 2013-04-25 2014-10-31 Pf Medicament Derives de la dolastatine 10 et d'auristatines
US10836821B2 (en) 2013-10-15 2020-11-17 Sorrento Therapeutics, Inc. Drug-conjugates with a targeting molecule and two different drugs
US10675355B2 (en) 2013-12-27 2020-06-09 Var2 Pharmaceuticals Aps VAR2CSA-drug conjugates
AU2014373574B2 (en) 2013-12-27 2020-07-16 Zymeworks Bc Inc. Sulfonamide-containing linkage systems for drug conjugates
WO2015162291A1 (en) 2014-04-25 2015-10-29 Pierre Fabre Medicament Igf-1r antibody-drug-conjugate and its use for the treatment of cancer
RU2685259C2 (ru) 2014-04-25 2019-04-17 Пьер Фабр Медикамент Конъюгат антитела и лекарственного средства и его применение для лечения рака
KR102494557B1 (ko) 2014-09-17 2023-02-02 자임워크스 비씨 인코포레이티드 세포독성 및 항유사분열성 화합물, 그리고 이를 이용하는 방법
AU2015358532C1 (en) 2014-12-03 2020-10-29 Genentech, Inc. Quaternary amine compounds and antibody-drug conjugates thereof
US10590165B2 (en) 2015-01-28 2020-03-17 Sorrento Therapeutics, Inc. Antibody drug conjugates
AU2016218840A1 (en) * 2015-02-15 2017-08-31 Jiangsu Hengrui Medicine Co., Ltd. Ligand-cytotoxicity drug conjugate, preparing method therefor, and application thereof
AU2016308539B2 (en) 2015-08-14 2019-01-24 Remegen Co., Ltd. Covalent linkers in antibody-drug conjugates and methods of making and using the same
TWI618697B (zh) 2015-11-03 2018-03-21 財團法人工業技術研究院 化合物、連接子－藥物、及配體－藥物耦合體
KR102445255B1 (ko) 2016-03-02 2022-09-22 에자이 알앤드디 매니지먼트 가부시키가이샤 에리불린-기반 항체-약물 콘주게이트 및 사용 방법
WO2018086139A1 (en) * 2016-11-14 2018-05-17 Hangzhou Dac Biotech Co., Ltd Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers
BR112019016139A2 (pt) 2017-02-08 2020-04-07 Bristol-Myers Squibb Company polipeptídio de relaxina modificada compreendendo um melhorador farmacocinético e usos do mesmo
US11851662B2 (en) 2017-06-02 2023-12-26 Ambrx, Inc. Methods and compositions for promoting non-natural amino acid-containing protein production
EP3773910A1 (en) 2018-03-29 2021-02-17 Ambrx, Inc. Humanized anti-prostate-specific membrane antigen (psma) antibody drug conjugates
CN109232712B (zh) * 2018-08-21 2021-08-03 联宁（苏州）生物制药有限公司 一种用于抗体药物偶联物的中间体的制备方法
US11833219B2 (en) 2019-09-29 2023-12-05 Mabplex International Co., Ltd. Method for producing antibody-drug conjugate intermediate by addition of acid and use thereof
CA3076714C (en) * 2019-09-29 2021-06-15 Mabplex International, Ltd. Method for producing antibody-drug conjugate intermediate by addition of acid and use thereof
WO2024077277A1 (en) 2022-10-07 2024-04-11 Ambrx, Inc. Drug linkers and antibody conjugates thereof

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7850A (en) 1850-12-24 Improvement in the manufacture of starch from maize
US971A (en) 1838-10-08 Mode of pbeventing dust from rising from threshing-machines when in
FR2504010B1 (fr) 1981-04-15 1985-10-25 Sanofi Sa Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4659839A (en) 1984-10-10 1987-04-21 Mallinckrodt, Inc. Coupling agents for radiolabeled antibody fragments
DE3680924D1 (de) 1985-01-14 1991-09-26 Neorx Corp Metall-radionuklid markiertes protein fuer diagnose und therapie.
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US4699784A (en) 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US6962981B1 (en) 1996-03-25 2005-11-08 Medarex, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US7381407B1 (en) 1996-03-25 2008-06-03 Medarex, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US6150508A (en) 1996-03-25 2000-11-21 Northwest Biotherapeutics, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US6107090A (en) 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
EP1062230B1 (en) 1998-03-05 2004-10-13 Chiron Corporation Method for increasing the serum half-life of a biologically active molecule
US6387888B1 (en) 1998-09-30 2002-05-14 American Foundation For Biological Research, Inc. Immunotherapy of cancer through expression of truncated tumor or tumor-associated antigen
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
CA2443757C (en) 2001-04-19 2016-09-27 The Scripps Research Institute In vivo incorporation of unnatural amino acids
US7514078B2 (en) 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
MXPA03010804A (es) 2001-06-01 2004-11-22 Cornell Res Foundation Inc Anticuerpos modificados para antigeno de membrana especifico de la prostata y usos de los mismos.
IL159422A0 (en) 2001-09-20 2004-06-01 Cornell Res Foundation Inc Methods and compositions for treating or preventing skin disorders using binding agents specific for prostate-specific membrane antigen
ES2606537T3 (es) 2001-10-23 2017-03-24 Psma Development Company L.L.C. Anticuerpos contra PSMA
AU2003300389B2 (en) 2002-12-22 2009-10-08 The Scripps Research Institute Protein arrays
US7910693B2 (en) 2004-04-19 2011-03-22 Proscan Rx Pharma Inc. Prostate cancer diagnosis and treatment
CA2564076C (en) * 2004-05-19 2014-02-18 Medarex, Inc. Chemical linkers and conjugates thereof
WO2006050262A2 (en) 2004-11-01 2006-05-11 The Regents Of The University Of California Compositions and methods for modification of biomolecules
WO2006069246A2 (en) * 2004-12-22 2006-06-29 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
ZA200704925B (en) * 2004-12-22 2009-11-25 Ambrx Inc Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
BRPI0607796A2 (pt) 2005-02-18 2009-06-13 Medarex Inc composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparação e uso do mesmo, e, composição farmacêutica
US8067006B2 (en) * 2005-04-06 2011-11-29 Immunomedics, Inc. Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
US7976852B2 (en) * 2005-04-26 2011-07-12 Eisai R&D Management Co., Ltd. Compositions and methods for cancer immunotherapy
WO2007002222A2 (en) * 2005-06-20 2007-01-04 Psma Development Company, Llc Psma antibody-drug conjugates
US8871720B2 (en) * 2005-07-07 2014-10-28 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus
JP2010512800A (ja) * 2006-12-18 2010-04-30 アンブルックス，インコーポレイテッド 非天然のアミノ酸およびポリペプチドを含んでいる組成物、これらが関連する方法、ならびにこれらの利用
DK2326350T3 (da) * 2008-09-08 2013-12-16 Psma Dev Company L L C Forbindelser til at dræbe psma-udtrykkende, taxanresistente cancerceller
CN102232085A (zh) * 2008-09-26 2011-11-02 Ambrx公司 修饰的动物促红细胞生成素多肽和其用途
SG195183A1 (en) * 2011-05-27 2013-12-30 Ambrx Inc Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
KR102030856B1 (ko) * 2011-05-27 2019-10-10 암브룩스, 인코포레이티드 비-천연 아미노산 연결된 돌라스타틴 유도체를 함유하는 조성물, 이를 수반하는 방법, 및 용도
WO2013068874A1 (en) 2011-11-11 2013-05-16 Pfizer Inc. Antibody-drug conjugates

Also Published As

Publication number Publication date
AU2013270686A1 (en) 2015-01-22
AU2017200877B2 (en) 2018-08-30
SG10201702176XA (en) 2017-04-27
MX363116B (es) 2019-03-11
IL258937A (en) 2018-06-28
EP2858676A1 (en) 2015-04-15
AU2017200877A1 (en) 2017-03-02
KR20150023563A (ko) 2015-03-05
WO2013185117A1 (en) 2013-12-12
NZ713941A (en) 2017-02-24
US10800856B2 (en) 2020-10-13
NZ703298A (en) 2016-04-29
IL258937B (en) 2019-08-29
MX2014015029A (es) 2015-03-03
KR102143664B1 (ko) 2020-08-11
MX2019002732A (es) 2023-02-23
CA2874854A1 (en) 2013-12-12
US20150152190A1 (en) 2015-06-04
SG11201408153YA (en) 2015-01-29
CN116514899A (zh) 2023-08-01
JP2015521590A (ja) 2015-07-30
CA2874854C (en) 2023-03-14
EP3536700A1 (en) 2019-09-11
IL235895B (en) 2018-05-31
IL235895A0 (en) 2015-01-29
CN104619349A (zh) 2015-05-13
ES2725329T3 (es) 2019-09-23
CN104619349B (zh) 2018-07-10
US20220033518A1 (en) 2022-02-03
CN108727466A (zh) 2018-11-02
CN108727466B (zh) 2023-04-28
EP2858676B1 (en) 2019-03-13
IL268538B (en) 2020-11-30
AU2013270686B2 (en) 2016-11-10
JP6425650B2 (ja) 2018-11-21
IL268538A (en) 2019-09-26

Similar Documents

Publication Publication Date Title
FR23C1020I2 (fr) Conjugues pyrrolobenzodiazepine-anticorps
IL268538B (en) Drug conjugates - antibody against membrane antigen specific for prostate cancer
DK2906251T3 (da) Pyrrolobenzodiazepin-anti-CD22-antistofkonjugater
BR112015008232A2 (pt) conjugados pirrolbenzodiazepina-anticorpo
IL236323B (en) Drug conjugates of anti–cd70 antibody
DK3117837T3 (da) Antistofformuleringer
DK2920304T3 (da) Oligonukleotidkonjugater
DK2934584T3 (da) Anti-gdf15-antistoffer
DK2850101T3 (da) Anti-FcRn-antistoffer
DK3444281T3 (da) Forbedrede peptidlægemidler
DK2920167T3 (da) Hydrazinyl-indol-forbindelser og konjugater
BR112015000530A2 (pt) vacina de antígeno micobacteriano.
BR112014029403A2 (pt) conjugados, anticorpo e formulação farmacêutica
BR112014033077A2 (pt) combinação de vacina.
BR112014025037A2 (pt) anticorpo ou um fragmento funcional do mesmo, nucleotídeo, vetor recombinante, célula, métodos para a produção de um anticorpo ou fragmento funcional, para detecção ou ensaio de fgfr2 humano iiib, para a identificação de um indivíduo receptor de uma composição farmacêutica, e, para identificar e para produzir uma substância, forma modificada, composição, e, reagente
CL2015003481A1 (es) Conjugados de anticuerpo fármaco
DK2841054T4 (da) Injicerbart præparat
DK2917244T3 (da) Aprotinin-afledte polypeptid-antistofkonjugater
DK2828292T3 (da) Jcv-neutraliserende antistoffer
DK3431504T3 (da) Antiphospholipase d4-antistof
DK3521315T3 (da) Anti-transglutaminase-2-antistoffer
BR112014030277A2 (pt) sistema médico
DK2935330T3 (da) Anti-notch3-antistoffer
DK2932264T3 (da) Nye MHC-uafhængige tumor-associerede antigener
CO7091176A2 (es) Diagnóstico farmacéutico